Premium
Triterpenoid CDDO‐methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease
Author(s) -
Dumont Magali,
Wille Elizabeth,
Calingasan Noel Y.,
Tampellini Davide,
Williams Charlotte,
Gouras Gunnar K.,
Liby Karen,
Sporn Michael,
Flint Beal M.,
Lin Michael T.
Publication year - 2009
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2009.05970.x
Subject(s) - oxidative stress , genetically modified mouse , amyloid (mycology) , inflammation , pathogenesis , antioxidant , transgene , alzheimer's disease , neuroscience , medicine , chemistry , disease , endocrinology , biology , pathology , biochemistry , gene
Oxidative stress is one of the earliest events in the pathogenesis of Alzheimer’s disease (AD) and can markedly exacerbate amyloid pathology. Modulation of antioxidant and anti‐inflammatory pathways represents an important approach for AD therapy. Synthetic triterpenoids have been found to facilitate antioxidant response and reduce inflammation in several models. We investigated the effect of the triterpenoid, 2‐Cyano‐3,12‐Dioxooleana‐1,9‐Dien‐28‐Oic acid‐MethylAmide (CDDO‐MA) in Tg19959 mice, which carry the human amyloid precursor protein with two mutations. These mice develop memory impairments and amyloid plaques as early as 2–3 months of age. CDDO‐MA was provided with chow (800 mg/kg) from 1 to 4 months of age. CDDO‐MA significantly improved spatial memory retention and reduced plaque burden, Aβ42 levels, microgliosis, and oxidative stress in Tg19959 mice.